Newspaper logo  
Local Gov’t Stories, Events


Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

Books, Films, Arts & Education

Ref. : Letters to the editor

Health Care & Environment

10.24 Inside big pharma's fight to block recreational marijuana

10.24 We sent a vegetarian to see if meatless burgers can convert carnivores

10.23 Dear Donald Trump: I'm an OB-GYN. There are no 9-month abortions.

10.23 China’s Wind Co. Profits, share price soar by 60%: 2 Turbines an Hour being Installed

10.23 The world’s first tidal energy farm could power 175,000 homes [similar project is underway in the Bay of Fundy]

10.22 Law to cut sex-selective abortions in Armenia 'putting lives at risk'

10.22 US energy shakeup continues as solar capacity set to triple

10.22 A three-bed house with £500 energy bills? How you too can slash your costs

10.22 Highlighting Damage of Lack of Clinic Funding, CDC Says STDs at All-Time High

10.22 Three Massive Mergers—Millions for One Bank and a Disaster for Food, Water, and Climate

10.21 Hillary Clinton vs Donald Trump on science, energy, and the climate

10.21 That's 4 straight debates without a single question on climate change. Good job, everyone.

10.21 Bottled Water or Tap: How Much Does Your Choice Matter?

10.21 We are approaching the Trumpocene, a new epoch where climate change is just a big scary conspiracy

10.21 Global warming continues; 2016 will be the hottest year ever recorded

10.21 Onshore windfarms more popular than thought, UK poll finds

10.21 Europe's offshore wind industry booming as costs fall

News Media Matters

10.23 The Crackdown on Dakota Access Pipeline Reporters Shows the Vital Role of Independent Media

10.23 How media outlets from around the world are reacting to the presidential campaign

10.22 Documentary film-makers face decades in prison for taping oil pipeline protests

Daily: FAIR Blog
The Daily Howler

US Politics, Policy & 'Culture'

10.23 AIR TRUMP: A SHORT PLAY [parody]


10.22 The Huge Corporate Tax Cut Hillary Clinton Doesn’t Talk About [is double-taxation on foreign income normal or out of step?]

10.22 Bernie Looks Ahead

Justice Matters

10.24 Police and hired assassins are killing land rights defenders. Let's end this violence

10.24 Tunisian coalition party fights for women's rights with gender violence bill

10.22 Senators Want to Know: Who's Actually Being Held Accountable at Wells Fargo?


10.20 Mass incarceration in America, explained in 22 maps and charts

High Crimes?

10.24 Philippines senator calls for Duterte to face crimes against humanity inquiry

Economics, Crony Capitalism

10.24 How Democrats Killed Their Populist Soul

10.24 Elizabeth Warren Warns Democrats Not To Cave On Corporate Tax Reform

10.23 Super-size my superyacht: the quest for bigger boats and gadgets


10.22 We Never Voted for Corporate Rule

10.21 Capitalism Is Doomed — Without Alternatives, So Are We


10.24 The Turks want Mosul and Aleppo "back."

10.24 Diary

10.24 Young, female and determined: how millennial social entrepreneurs are changing the world

10.24 Q&A: what happens now to the Calais refugees?

10.23 America, land of opportunity? Not for young people, study says

10.20 Elon Musk says fully self-driving Tesla cars already being built

10.19 Everything You Need to Know About the Momentous Habitat III

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
This site Web
  Big Pharma Wins Big in Health Care Reform


Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.

Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.

Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.

Public Service Ads:
Verifiable Voting in Maryland